ATE519779T1 - An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen - Google Patents

An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen

Info

Publication number
ATE519779T1
ATE519779T1 AT01402406T AT01402406T ATE519779T1 AT E519779 T1 ATE519779 T1 AT E519779T1 AT 01402406 T AT01402406 T AT 01402406T AT 01402406 T AT01402406 T AT 01402406T AT E519779 T1 ATE519779 T1 AT E519779T1
Authority
AT
Austria
Prior art keywords
glu
pro
compositions containing
motiv
proteins
Prior art date
Application number
AT01402406T
Other languages
English (en)
Inventor
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Univ Paris Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Univ Paris Sud filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE519779T1 publication Critical patent/ATE519779T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
AT01402406T 2001-09-19 2001-09-19 An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen ATE519779T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01402406A EP1295895B1 (de) 2001-09-19 2001-09-19 An das Glu-Pro Motiv-bindende Proteine und Peptide, diese enthaltende therapeutische Zusammensetzungen und deren Anwendungen

Publications (1)

Publication Number Publication Date
ATE519779T1 true ATE519779T1 (de) 2011-08-15

Family

ID=8182881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01402406T ATE519779T1 (de) 2001-09-19 2001-09-19 An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen

Country Status (7)

Country Link
US (1) US20040171551A1 (de)
EP (2) EP1295895B1 (de)
JP (1) JP2005507249A (de)
AT (1) ATE519779T1 (de)
AU (1) AU2002343126A1 (de)
CA (1) CA2460665A1 (de)
WO (1) WO2003035682A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
BR112016018408A2 (pt) 2014-03-14 2017-12-26 Immutep Sas moléculas de anticorpo à lag-3 e usos das mesmas
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
SI3631454T1 (sl) 2017-05-30 2023-12-29 Bristol-Myers Squibb Company Zdravljenje lag-3 pozitivnih tumorjev
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT843557E (pt) * 1995-07-21 2003-03-31 Applied Research Systems Metodos para detectar indentificar isolar e etiquetar e abordar selectivamente linfocitos th1 por intermedio da proteina lag-3
EP0900841A1 (de) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Spleissvarianten von LAG-3
EP0893507A1 (de) * 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
US5919616A (en) * 1997-12-12 1999-07-06 Aurx, Inc. Serological assay for herpes

Also Published As

Publication number Publication date
AU2002343126A1 (en) 2003-05-06
WO2003035682A3 (en) 2003-09-25
US20040171551A1 (en) 2004-09-02
EP1295895A1 (de) 2003-03-26
EP1427753A2 (de) 2004-06-16
EP1295895B1 (de) 2011-08-10
CA2460665A1 (en) 2003-05-01
WO2003035682A2 (en) 2003-05-01
JP2005507249A (ja) 2005-03-17

Similar Documents

Publication Publication Date Title
ATE519779T1 (de) An das glu-pro motiv-bindende proteine und peptide, diese enthaltende therapeutische zusammensetzungen und deren anwendungen
HUP0002454A2 (hu) D-Vitamin-molekularésszel rendelkező konjugátumok és ilyen konjugátumokat tartalmazó gyógyászati készítmények
BR0107613A (pt) Bloqueio do crescimento de axÈnios mediado por receptor nogo
CY1117239T1 (el) Συνδυαστικες συνθεσεις διπλοκοκκου του neisser
PT804456E (pt) Conjugados de acidos nucleicos dos peptidos
BRPI0417341A (pt) fator ix glicopeguilado
BR9711795A (pt) Peptìdeos tendo propriedades antiproliferativas
CO5050400A1 (es) Proteina de chlamydia, secuencia de genes y anticuerpos para ello
DE60238993D1 (de) Hybrid und tandemproteine von neisseria sp
ES2063278T3 (es) Proteina morfogenetica de hueso.
CA2181150A1 (en) Biologically Active Peptides from Functional Domains of Bactericidal/Permeability-Increasing Protein and Uses Thereof
WO2006031811A3 (en) Glycopegylated interferon alpha
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
CA2158058A1 (en) Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
DE68916932T2 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
DE60020344D1 (de) Cyanovirin konjugate, matrix-verankertes cyanovirin und anti-cyanovirin antikörper, und verwandte zusammensetzungen und anwendungen
DK1025236T3 (da) Human checkpoint kinase, HCDS1, præparater og fremgangsmåde
DE69636285D1 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
PT896615E (pt) Peptido proveniente de uma forma soluvel de acetilcolinesterase activo como modulador dos canais de calcio
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE69524971D1 (de) Neue familie von proteaseinhibitoren und andere biologisch aktive substanzen
DE69309790T2 (de) Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen
ID30183A (id) Turunan-turunan peptida berat molekul rendah sebagai penghambat-penghambat interaksi laminin/nidogen
DE50011068D1 (de) Fragmente des virus proteins 2 oder 3 des polyomavirus als fähren für wirkstoffe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties